On Friday 03/17/2023 the closing price of the Gilead Sciences Inc. share was $77.31 on NAS.
Compared to the opening price on Friday 03/17/2023 on NAS of $79.76, this is a drop of 3.17%.
Gilead Sciences Inc.'s market capitalization is $99.38 B by 1.25 B shares outstanding.
Is Gilead Sciences stock a Buy, Sell or Hold?
Gilead Sciences stock has received a consensus rating of hold. The average rating score is A3 and is based on 23 buy ratings, 29 hold ratings, and 2 sell ratings.What was the 52-week low for Gilead Sciences stock?
The low in the last 52 weeks of Gilead Sciences stock was 57.17. According to the current price, Gilead Sciences is 135.23% away from the 52-week low.What was the 52-week high for Gilead Sciences stock?
The high in the last 52 weeks of Gilead Sciences stock was 89.61. According to the current price, Gilead Sciences is 86.27% away from the 52-week high.What are analysts forecasts for Gilead Sciences stock?
The 54 analysts offering price forecasts for Gilead Sciences have a median target of 78.22, with a high estimate of 112.00 and a low estimate of 56.00. The median estimate represents a 98.83 difference from the last price of 77.31.Gilead Sciences Stock Snapshot
77.31
Bid
25,600.00
Bid Size
77.33
Ask
100.00
Ask Size
3/17/2023
Date
8:00 PM
Time
9.96 M
Volume
79.85
Prev. Close
79.76
Open
99.38 B
Market Cap
1.25 B
Number of Shares
76.53
Day Low
79.76
Day High
77.31
57.17
52 Week Low
89.61
52 Week High
77.31
3.31
Dividend
4.15
Dividend Yield
11.70
P/E Ratio
99.92
Free Float in %
6.84
EPS 2023
19.32
Book Value per Share
7.48
Cash Flow per Share
Gilead Sciences News More News
Gilead Sciences Historical Prices
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
Gilead Sciences Analyst Data
Total Analysts: 54
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 56.00
Median: 78.22
Highest: 112.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Gilead Sciences Analyst Opinions
- All
- Buy
- Hold
- Sell
| 03/06/23 | RBC Capital Markets | Maintained Hold | $86 | ||
| 02/14/23 | Mizuho | Maintained Buy | $101 | ||
| 02/03/23 | SVB Leerink | Maintained Hold | $91 | ||
| 02/03/23 | Morgan Stanley | Maintained Hold | $81 | ||
| 02/03/23 | Piper Sandler | Maintained Buy | $112 | ||
| 01/24/23 | Morgan Stanley | Maintained Hold | $80 | ||
| 01/19/23 | Piper Sandler | Maintained Buy | $111 | ||
| 01/18/23 | Barclays Capital | Maintained Hold | $84 | ||
| 01/03/23 | Wells Fargo & Co | Maintained Hold | $90 | ||
| 01/03/23 | RBC Capital Markets | Downgraded to Hold | $87 | ||
| 12/13/22 | Bank of America Merrill Lynch | Maintained Hold | $85 | ||
| 12/01/22 | Morgan Stanley | Maintained Hold | $81 | ||
| 11/08/22 | Cowen and Company, LLC | Maintained Buy | $90 | ||
| 11/08/22 | Mizuho | Maintained Buy | $88 | ||
| 11/01/22 | SVB Leerink | Maintained Hold | $81 | ||
| 10/31/22 | Maxim Group | Maintained Buy | $92 | ||
| 10/31/22 | Barclays Capital | Upgraded to Hold | $76 | ||
| 10/28/22 | Morgan Stanley | Maintained Hold | $68 | ||
| 10/28/22 | RBC Capital Markets | Maintained Buy | $82 | ||
| 10/28/22 | Wells Fargo & Co | Maintained Hold | $75 | ||
| 10/28/22 | Piper Sandler | Upgraded to Buy | $96 | ||
| 10/13/22 | Morgan Stanley | Maintained Hold | $67 | ||
| 10/12/22 | Barclays Capital | Maintained Sell | $60 | ||
| 10/04/22 | J.P. Morgan | Upgraded to Buy | $80 | ||
| 09/13/22 | Wells Fargo & Co | Maintained Hold | $74 | ||
| 07/26/22 | Piper Sandler | Maintained Hold | $71 | ||
| 07/15/22 | Morgan Stanley | Maintained Hold | $65 | ||
| 07/13/22 | Cantor Fitzgerald | Maintained Hold | $70 | ||
| 05/23/22 | SVB Leerink | Maintained Hold | $68 | ||
| 05/17/22 | Piper Sandler | Maintained Hold | $69 | ||
| 04/29/22 | BMO Capital Markets | Maintained Buy | $63 | ||
| 04/29/22 | Piper Sandler | Maintained Hold | $73 | ||
| 04/12/22 | Morgan Stanley | Maintained Hold | $63 | ||
| 04/12/22 | RBC Capital Markets | Maintained Buy | $77 | ||
| 04/04/22 | Piper Sandler | Maintained Hold | $71 | ||
| 03/22/22 | Wells Fargo & Co | Maintained Hold | $63 | ||
| 03/10/22 | Barclays Capital | Maintained Sell | $56 | ||
| 03/08/22 | RBC Capital Markets | Maintained Buy | $77 | ||
| 02/28/22 | BMO Capital Markets | Downgraded to Buy | $65 | ||
| 02/08/22 | Mizuho | Maintained Buy | $75 | ||
| 02/02/22 | Morgan Stanley | Maintained Hold | $69 | ||
| 01/28/22 | Argus Research Company | Upgraded to Buy | $75 | ||
| 01/18/22 | Morgan Stanley | Maintained Hold | $72 | ||
| 01/06/22 | Morgan Stanley | Downgraded to Hold | $74 | ||
| 12/09/21 | Wells Fargo & Co | Maintained Hold | $72 | ||
| 12/06/21 | Goldman Sachs | Maintained Hold | $80 | ||
| 10/29/21 | SVB Leerink | Maintained Buy | $75 | ||
| 10/12/21 | Morgan Stanley | Maintained Buy | $84 | ||
| 07/30/21 | RBC Capital Markets | Maintained Buy | $84 | ||
| 07/30/21 | SVB Leerink | Maintained Buy | $77 |
Gilead Sciences Estimates* in USD
| 2023 | 2024 | 2025 | 2026 | 2027 | |
|---|---|---|---|---|---|
| Revenue | 26,732 | 27,258 | 28,122 | 28,863 | 30,097 |
| Dividend | 3.31 | 3.61 | 3.32 | 3.59 | 3.65 |
| Dividend Yield (in %) | 4.15 % | 4.51 % | 4.15 % | 4.49 % | 4.57 % |
| EPS | 6.84 | 7.23 | 7.51 | 7.75 | 8.45 |
| P/E Ratio | 11.38 | 10.78 | 10.37 | 10.06 | 9.22 |
| EBIT | 11,525 | 11,981 | 12,301 | 12,586 | 13,352 |
| EBITDA | 12,720 | 13,365 | 13,408 | 12,401 | 17,155 |
| Net Profit | 8,617 | 8,931 | 9,245 | 9,483 | 10,239 |
| Net Profit Adjusted | 8,617 | 8,987 | 9,306 | 9,535 | 10,344 |
| Pre-Tax Profit | 10,389 | 11,249 | 11,382 | 11,760 | 12,925 |
| Net Profit (Adjusted) | 9,454 | 9,661 | 10,167 | 9,569 | 11,447 |
| EPS (Non-GAAP) ex. SOE | - | - | - | 7.78 | 8.48 |
| EPS (GAAP) | 5.52 | 5.76 | 5.98 | 5.95 | 6.61 |
| Gross Income | 21,651 | 22,456 | 23,439 | 24,503 | 26,687 |
| Cash Flow from Investing | -779 | -795 | -833 | -911 | -928 |
| Cash Flow from Operations | 9,919 | 10,042 | 10,598 | 11,379 | 12,005 |
| Cash Flow from Financing | -5,621 | -4,056 | -5,203 | -5,866 | -5,898 |
| Cash Flow per Share | 7.48 | 7.86 | 9.02 | - | - |
| Free Cash Flow | 9,211 | 9,565 | 9,585 | 8,444 | 11,677 |
| Free Cash Flow per Share | - | - | - | - | - |
| Book Value per Share | 19.32 | 22.00 | 24.79 | 22.24 | - |
| Net Debt | 13,702 | 8,124 | 2,662 | 3,379 | - |
| Research & Development Exp. | 5,374 | 5,514 | 5,714 | 5,837 | 6,004 |
| Capital Expenditure | 666 | 666 | 675 | 664 | 670 |
| Selling, General & Admin. Exp. | 5,474 | 5,554 | 5,729 | 5,876 | 5,984 |
| Shareholder’s Equity | 26,382 | 30,787 | 36,484 | 40,340 | 45,713 |
| Total Assets | 69,387 | 74,208 | 79,815 | 81,770 | 86,687 |
|
Previous Quarter ending 12/31/22 |
Current Quarter ending 03/31/23 |
Next Quarter ending 06/30/23 |
Current Year ending 12/31/23 |
Next Year ending 12/31/24 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 22 | 21 | 21 | 24 | 23 |
| Average Estimate | 1.518 USD | 1.550 USD | 1.709 USD | 6.844 USD | 7.226 USD |
| Year Ago | 0.690 USD | 2.120 USD | 1.580 USD | 7.260 USD | 6.844 USD |
| Publish Date | 2/2/2023 | 5/4/2023 | 8/1/2023 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 20 | 19 | 18 | 23 | 22 |
| Average Estimate | 6,635 USD | 6,300 USD | 6,473 USD | 26,732 USD | 27,258 USD |
| Year Ago | 7,244 USD | 6,590 USD | 6,260 USD | 27,281 USD | 26,732 USD |
| Publish Date | 2/2/2023 | 5/4/2023 | 8/1/2023 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Gilead Sciences Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Parsey Merdad | 03/12/2023 | 6,126.00 | 70,130.00 | 78.99 | Sell | No |
| Dickinson Andrew D | 03/09/2023 | 4,849.00 | 111,188.00 | 79.50 | Sell | No |
| Parsey Merdad | 03/09/2023 | 5,328.00 | 76,256.00 | 79.50 | Sell | No |
| Mercier Johanna | 03/09/2023 | 5,116.00 | 82,225.00 | 79.50 | Sell | No |
| Patterson Sandra | 03/09/2023 | 801.00 | 26,212.00 | 79.50 | Sell | No |
| O'Day Daniel Patrick | 03/09/2023 | 14,017.00 | 375,766.00 | 79.50 | Sell | No |
| Dickinson Andrew D | 03/09/2023 | 7,394.00 | 116,037.00 | n/a | Buy | No |
| Dickinson Andrew D | 03/09/2023 | 3,025.00 | 108,643.00 | n/a | Buy | No |
| Parsey Merdad | 03/09/2023 | 7,999.00 | 81,584.00 | n/a | Buy | No |
| Parsey Merdad | 03/09/2023 | 3,455.00 | 73,585.00 | n/a | Buy | No |
| Mercier Johanna | 03/09/2023 | 7,951.00 | 87,341.00 | n/a | Buy | No |
| Mercier Johanna | 03/09/2023 | 3,025.00 | 79,390.00 | n/a | Buy | No |
| Patterson Sandra | 03/09/2023 | 1,320.00 | 27,013.00 | n/a | Buy | No |
| Patterson Sandra | 03/09/2023 | 1,601.00 | 25,693.00 | n/a | Buy | No |
| O'Day Daniel Patrick | 03/09/2023 | 10,800.00 | 389,783.00 | n/a | Buy | No |
| O'Day Daniel Patrick | 03/09/2023 | 19,488.00 | 378,983.00 | n/a | Buy | No |
| Lofton Kevin E | 03/08/2023 | 8,442.00 | 8,442.00 | 52.38 | Buy | No |
| O'Day Daniel Patrick | 02/28/2023 | 4,842.00 | 359,495.00 | 79.59 | Sell | No |
| Parsey Merdad | 02/28/2023 | 12,984.00 | 70,130.00 | 79.96 | Sell | No |
| O'Day Daniel Patrick | 02/28/2023 | 11,362.00 | 364,337.00 | n/a | Buy | No |
| Telman Deborah H | 02/14/2023 | 376.00 | 376.00 | 56.38 | Buy | No |
| Parsey Merdad | 02/14/2023 | 376.00 | 83,114.00 | 56.38 | Buy | No |
| Dickinson Andrew D | 02/14/2023 | 376.00 | 105,618.00 | 56.38 | Buy | No |
| Wilfong Diane E. | 02/05/2023 | 565.00 | 32,010.00 | 86.36 | Sell | No |
| Dickinson Andrew D | 02/05/2023 | 531.00 | 105,242.00 | 86.36 | Sell | No |
Gilead Sciences Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2022 | Gilead Sciences Inc. | 2.92 | 3.40 | USD |
| 2021 | Gilead Sciences Inc. | 2.84 | 3.91 | USD |
| 2020 | Gilead Sciences Inc. | 2.72 | 4.67 | USD |
| 2019 | Gilead Sciences Inc. | 2.52 | 3.88 | USD |
| 2018 | Gilead Sciences Inc. | 2.28 | 3.65 | USD |
| 2017 | Gilead Sciences Inc. | 2.08 | 2.90 | USD |
| 2016 | Gilead Sciences Inc. | 1.84 | 2.57 | USD |
| 2015 | Gilead Sciences Inc. | 1.29 | 1.27 | USD |
| 2014 | Gilead Sciences Inc. | - | - | USD |
| 2013 | Gilead Sciences Inc. | - | - | USD |
| 2012 | Gilead Sciences Inc. | - | - | USD |
| 2011 | Gilead Sciences Inc. | - | - | USD |
| 2010 | Gilead Sciences Inc. | - | - | USD |
| 2009 | Gilead Sciences Inc. | - | - | USD |
| 2008 | Gilead Sciences Inc. | - | - | USD |
| 2007 | Gilead Sciences Inc. | - | - | USD |
| 2006 | Gilead Sciences Inc. | - | - | USD |
| 2005 | Gilead Sciences Inc. | - | - | USD |
| 2004 | Gilead Sciences Inc. | - | - | USD |
| 2003 | Gilead Sciences Inc. | - | - | USD |
*Yield of the Respective Date
Gilead Sciences Inc. Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 1.550 USD | Q1 2023 Earnings Release | 05/04/2023 |
| Earnings Report | 1.709 USD | Q2 2023 Earnings Release | 08/01/2023 |
| Earnings Report | - | Q3 2023 Earnings Release | 10/26/2023 |
| Earnings Report | - | Q4 2023 Earnings Release | 02/06/2024 |
Gilead Sciences Inc. Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Earnings Report | 1.670 USD | Q4 2022 Earnings Release | 02/02/2023 |
Gilead Sciences Profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Moody’s Daily Credit Risk Score
Gilead Sciences Shareholder
| Owner | in % |
|---|---|
| Freefloat | 99.92 |
| Vanguard Group, Inc. (Subfiler) | 8.50 |
| Capital Research & Management Co. (World Investors) | 5.49 |
| State Street Corp. | 4.70 |
| BlackRock Fund Advisors | 4.68 |
| Capital Research & Management Co. (Global Investors) | 4.35 |
| Vanguard Total Stock Market Index Fund | 3.08 |
| Dodge & Cox | 2.86 |
| American Funds Income Fund of America | 2.51 |
| Vanguard 500 Index Fund | 2.32 |
| BlackRock Institutional Trust Co. NA | 2.31 |
| Dodge & Cox Stock Fund | 2.01 |
| Geode Capital Management LLC | 1.90 |
| American Mutual Fund | 1.62 |
| BlackRock Asset Management Ireland Ltd. | 1.10 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
Gilead Sciences Management
| Name | Job |
|---|---|
| Daniel P. O'Day | Chairman & Chief Executive Officer |
| Johanna Mercier | Chief Commercial Officer |
| Andrew D. Dickinson | Chief Financial Officer |
| Merdad V. Parsey | Chief Medical Officer |
| Stacey Y. Ma | EVP-Pharmaceutical Development & Manufacturing |
| Adam Levy | Executive Director-Investor Relations |
| Jyoti K. Mehra | Executive Vice President-Human Resources |
| Flavius Martin | Executive Vice President-Research |
| Jacquie Ross | Head-Investor Relations |
| Javier J. Rodriguez | Independent Director |
| Jeffrey A. Bluestone | Independent Director |
| Sandra J. Horning | Independent Director |
| Anthony Welters | Independent Director |
| Harish M. Manwani | Independent Director |
| Jacqueline K. Barton | Independent Director |
| Kelly A. Kramer | Independent Director |
| Kevin E. Lofton | Lead Independent Director |
| Sandra K. Patterson | SVP, Chief Accounting Officer & Controller |
| Deborah H. Telman | Secretary, EVP-Corporate Affairs & General Counsel |
| Janet Dorling | Senior VP-Global Commercial Product Strategy |
| William Grossman | Senior VP-Oncology Clinical Development |
| Linda Slanec Higgins | Senior VP-Research & External Innovation |
| Joydeep Ganguly | Senior Vice President-Corporate Operations |
| Mark Genovese | Senior Vice President-Inflammation Development |
| Dustin Haines | Vice President & General Manager-Asia 5 |
| Melissa Grigorieff Koomey | Vice President-Global Commercial Operations |
| Tomas Cihlar | Vice President-Virology |